Lantus Solostar

Insulin glargine, the active ingredient in Lantus Solostar, is a long‑acting insulin analog presented as a solution for subcutaneous use. It provides basal insulin coverage to help manage blood glucose levels in individuals with diabetes mellitus, including both type 1 and type 2 disease.

GNH USA supplies Lantus Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable global distribution. Clients benefit from consistent product availability and regulatory compliance across markets.

Lantus Solostar, a long‑acting insulin analog, is used to control hyperglycemia in diabetes mellitus.

- Type 1 diabetes mellitus: provides basal insulin to maintain stable fasting glucose and reduce glycemic excursions. - Type 2 diabetes mellitus: adds basal insulin when oral agents are insufficient to achieve target glucose levels. - Insulin deficiency (basal insulin requirement): supplies steady insulin levels to lower fasting blood glucose and support overall glycemic control.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: gradual increase associated with improved glucose utilization. - Lipodystrophy: localized changes in fat tissue at injection sites. - Edema: mild fluid retention, often peripheral.

Serious or Rare Side Effects: - Severe hypoglycemia: neurological impairment requiring immediate assistance. - Allergic reactions: rash, urticaria, or angioedema. - Anaphylaxis: rare, potentially life‑threatening systemic reaction. - Insulin antibody formation: may alter insulin efficacy. - Ketoacidosis: rare if insulin effect is insufficient.

Lantus Solostar requires careful monitoring and patient education.

- Blood glucose monitoring: check levels regularly to adjust dose as needed. - Dose adjustments during illness: may need temporary increase to maintain control. - Alcohol consumption: can mask hypoglycemia symptoms; use with caution. - Renal impairment: reduced clearance may increase hypoglycemia risk. - Hypoglycemia awareness: educate patients on recognizing early signs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lantus Solostar may interact with several medications affecting glucose homeostasis.

Major Interactions (Avoid): - Concurrent use with other rapid‑acting insulins: heightened risk of severe hypoglycemia. - Combination with meglitinides: additive glucose‑lowering effect can precipitate hypoglycemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask typical hypoglycemia symptoms such as tachycardia. - ACE inhibitors: can potentiate insulin’s glucose‑lowering action. - Oral contraceptives: may slightly alter insulin sensitivity and glucose tolerance. - Corticosteroids: can increase blood glucose, requiring dose reassessment.